Richard A Chizzonite

US Patent:

6683046, Jan 27, 2004

Filed:

Jun 2, 1995

Appl. No.:

08/459151

Inventors:

Maurice Kent Gately - Montville NJ
Ulrich Andreas Gubler - Glen Ridge NJ
Jeffrey David Hulmes - Ringwood NJ
Frank John Podlaski - New City NY
Alvin Seth Stern - Passaic Park NJ
Richard Anthony Chizzonite - South Kent CT
Yu-Ching Eugene Pan - Pine Brook NJ

Assignee:

Hoffmann-La Roche Inc. - Nutley NJ

International Classification:

C07K 1400

US Classification:

514 2, 530351, 530350, 530399, 424 851, 424 852

Abstract:

The present invention is a novel cytokine protein called IL-12 or Cytotoxic Lymphocyte Maturation Factor (CLMF) which is produced and synthesized by human NC-37 B lymphoblastoid cells (American Type Culture Collection, Rockville, Md. ). CLMF synergistically induces with low concentrations of IL-2 the cytolytic activity of Lymphokine Activated Killer (LAK) cells, and CLMF is capable of stimulating T-cell growth. Also claimed are the cloned gene for CLMF, its recombination in a suitable vector, the transformed cells containing said vector, the recombinant protein produced by the transformed cells and antibodies to CLMF.

US Patent:

8110187, Feb 7, 2012

Filed:

Oct 8, 2002

Appl. No.:

10/267565

Inventors:

Maurice Kent Gately - Montville NJ, US
Ulrich Andreas Gubler - Glen Ridge NJ, US
Jeffrey David Hulmes - Ringwood NJ, US
Frank John Podlaski - New City NY, US
Alvin Seth Stern - Passaic Park NJ, US
Richard Anthony Chizzonite - South Kent CT, US
Yu-Ching Eugene Pan - Pine Brook NJ, US

Assignee:

Hoffman-La Roche Inc. - Nutley NJ

International Classification:

A61K 39/395
C07K 16/24

US Classification:

4241301, 4241581, 5303881, 53038823

Abstract:

The present invention is a novel cytokine protein called IL-12 or Cytotoxic Lymphocyte Maturation Factor (CLMF) which is produced and synthesized by human NC-37 B lymphoblastoid cells (American Type Culture Collection, Rockville, Md. ). CLMF synergistically induces with low concentrations of IL-2 the cytolytic activity of Lymphokine Activated Killer (LAK) cells, and CLMF is capable of stimulating T-cell growth. Also claimed are the cloned gene for CLMF, its recombination in a suitable vector, the transformed cells containing said vector, the recombinant protein produced by the transformed cells and antibodies to CLMF.

US Patent:

20030175311, Sep 18, 2003

Filed:

Oct 9, 2002

Appl. No.:

10/267430

Inventors:

Mary-Helen Binger - Hopewell NJ, US
Richard Chizzonite - South Kent CT, US
Richard Kramer - West Orange NJ, US
Peter Lomedico - Montclair NJ, US
Stephen McAndrew - Meriden CT, US
Werner Altenburger - Muenchenstein, CH

Assignee:

ALPHARMA INC.

International Classification:

A61K039/012
C07H021/04
C12N001/10
C12P021/02
C07K014/455
C12N015/74

US Classification:

424/271100, 530/350000, 536/023700, 435/069100, 435/320100, 435/258400

Abstract:

This invention provides DNA sequences coding for Eimeria surface antigens, recombinant vectors containing such DNA sequences, transformed microorganisms containing such vectors and methods for producing the antigens using the transformed microorganisms. Methods are also provided for protecting poultry against coccidiosis using the Eimeria surface antigens. The surface antigens can be administered for such protection either as purified proteins or in the form of DNA encoding the proteins in a suitable viral vector such as vaccinia virus.

US Patent:

20050118169, Jun 2, 2005

Filed:

Sep 9, 2004

Appl. No.:

10/937596

Inventors:

Ilse Bartke - Bernried, DE
Francis Carr - Aberdeenshire, GB
Richard Chizzonite - South Kent CT, US
Elsie Eugui - Belmont CA, US
Georg Fertig - Penzberg, DE
Anita Hamilton - Aberdeen, GB
Martin Lanzendoerfer - Muenchen, DE
Petra Rueger - Penzberg, DE
Ralf Schumacher - Penzberg, DE
Theresa Truitt - Bloomfield NJ, US

International Classification:

A61K039/395
C07H021/04
C07K016/28
C12N005/06

US Classification:

424143100, 530388220, 536023530, 435069100, 435320100, 435334000

Abstract:

The present invention relates to antibodies against interleukin-1 receptor (IL-1R), methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof. The antibodies of the present invention are particularly useful for treating a variety of inflammatory diseases including, but not limited to, rheumatoid arthritis.

US Patent:

20090191187, Jul 30, 2009

Filed:

Feb 13, 2009

Appl. No.:

12/370628

Inventors:

Ilse Bartke - Bernried, DE
Francis Carr - Aberdeenshire, GB
Richard Anthony Chizzonite - South Kent CT, US
Elsie M. Eugui - Belmont CA, US
Georg Fertig - Penzberg, DE
Anita Hamilton - Aberdeen, GB
Martin Lanzendoerfer - Muenchen, DE
Petra Rueger - Penzberg, DE
Ralf Schumacher - Penzberg, DE
Theresa Patricia Truitt - Bloomfield NJ, US

International Classification:

A61K 39/395
C12P 21/00
C12N 5/12
C12N 15/63
C07K 16/24
C12N 15/12
A61P 29/00

US Classification:

4241301, 435 696, 435325, 435346, 435358, 4353201, 5303891, 5303873, 536 235

Abstract:

The present invention relates to antibodies against interleukin-1 receptor (IL-1R), methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof. The antibodies of the present invention are particularly useful for treating a variety of inflammatory diseases including, but not limited to, rheumatoid arthritis.

US Patent:

60460121, Apr 4, 2000

Filed:

Jan 27, 1997

Appl. No.:

8/789350

Inventors:

Richard Anthony Chizzonite - South Kent CT
Theresa Patricia Truitt - Bloomfield NJ

Assignee:

Hoffmann-La Roche Inc. - Nutley NJ

International Classification:

G01N 33567
G01N 3353
G01N 33566
C07K 1600

US Classification:

435 721

Abstract:

This disclosure relates to novel antibodies specific to the recently discovered receptor to human interleukin 12 (IL-12R). The antibodies to IL-12R, most preferably, the monoclonal antibodies to that protein, are useful in determining the status of the human immune system and as diagnostic reagents or potential therapeutic reagents for conditions involving imbalances in IL-12 levels or cell types sensitive to IL-12 activation. Further aspects of the disclosure relate to methods of producing and purifying such novel antibodies and hybridoma cell lines capable of their production. Another aspect of the disclosure relates to an immunoprecipitation assay for the detection of solubilized IL-12R which employs, in a preferred embodiment, monoclonal antibodies to the receptor of the present invention covalently bound to Protein G-Sepharose resin.

US Patent:

56610157, Aug 26, 1997

Filed:

Dec 20, 1991

Appl. No.:

7/812349

Inventors:

Mary-Helen Binger - Hopewell NJ
Richard Anthony Chizzonite - South Kent CT
Richard Allen Kramer - West Orange NJ
Peter Thomas Lomedico - Montclair NJ
Stephen J. McAndrew - Meriden CT
Werner Altenburger - Muenchenstein, CH

Assignee:

Hoffmann-La Roche Inc. - Nutley NJ

International Classification:

C12N 1500

US Classification:

4351723

Abstract:

This invention provides DNA sequences coding for Eimeria surface antigens, recombinant vectors containing such DNA sequences, transformed microorganisms containing such vectors, and methods for producing the antigens using the transformed microorganisms. Methods are also provided for protecting poultry against coccidiosis using the Eimeria surface antigens. The surface antigens can be administered for such protection either as purified proteins or in the form of DNA encoding the proteins in a suitable viral vector such as vaccinia virus.

US Patent:

57805970, Jul 14, 1998

Filed:

Jun 2, 1995

Appl. No.:

8/460061

Inventors:

Maurice Kent Gately - Montville NJ
Ulrich Andreas Gubler - Glen Ridge NJ
Jeffrey David Hulmes - Ringwood NJ
Frank John Podlaski - New City NY
Alvin Seth Stern - Passaic Park NJ
Richard Anthony Chizzonite - South Kent CT
Yu-Ching Eugene Pan - Pine Brook NJ

Assignee:

Hoffmann-La Roche Inc. - Nutley NJ

International Classification:

C07K 1624
C12P 2108

US Classification:

53038823

Abstract:

The present invention relates to antibodies which bind to a novel cytotoxic lymphocyte maturation factor. When bound to the cytotoxic lymphocyte maturation factor, the antibodies can neutralize bioactivity of the factor.